E-drug: Re: Amodiaquine
-------------------------------------------------------------------------
The fact that amodiaquine was on the list in 1977 off in 79, on in
83 and off again in 87 may have indicated that the committee
needed to be careful.
Also the fact that there was a 6% neutropenia rate in the clinical
trial reported indicated that the safety concerns were serious. The
Roll Back Malaria program have been encouraged to address these
safety issues and resubmit. And of course countries can still make
their own decisions. Ghana for example have never removed the
drug from their list.
Richard Laing
Associate Professor of International Health
Boston University School of Public Health
715 Albany St, T4W, Boston MA 02118 USA
Tel 617 414-1444 Fax 617 638-4476
E-mail richardl@bu.edu
--
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@usa.healthnet.org
Information and archives: http://www.healthnet.org/programs/edrug.html